- Home
- ATNM vs FBIO Comparison
ATNM vs FBIO Comparison
Compare ATNM & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNM
- FBIO
- Stock Information
- Founded
- ATNM 2000
- FBIO 2006
- Country
- ATNM United States
- FBIO United States
- Employees
- ATNM N/A
- FBIO N/A
- Industry
- ATNM Biotechnology: Pharmaceutical Preparations
- FBIO Biotechnology: Pharmaceutical Preparations
- Sector
- ATNM Health Care
- FBIO Health Care
- Exchange
- ATNM Nasdaq
- FBIO Nasdaq
- Market Cap
- ATNM 56.5M
- FBIO 48.2M
- IPO Year
- ATNM N/A
- FBIO N/A
- Fundamental
- Price
- ATNM $1.73
- FBIO $1.81
- Analyst Decision
- ATNM Strong Buy
- FBIO Strong Buy
- Analyst Count
- ATNM 5
- FBIO 4
- Target Price
- ATNM $14.20
- FBIO $16.33
- AVG Volume (30 Days)
- ATNM 285.8K
- FBIO 957.9K
- Earning Date
- ATNM 10-31-2024
- FBIO 11-12-2024
- Dividend Yield
- ATNM N/A
- FBIO N/A
- EPS Growth
- ATNM N/A
- FBIO N/A
- EPS
- ATNM N/A
- FBIO N/A
- Revenue
- ATNM $81,000.00
- FBIO $82,624,000.00
- Revenue This Year
- ATNM $186.10
- FBIO N/A
- Revenue Next Year
- ATNM $19,248.94
- FBIO $81.63
- P/E Ratio
- ATNM N/A
- FBIO N/A
- Revenue Growth
- ATNM 80.00
- FBIO 31.68
- 52 Week Low
- ATNM $1.33
- FBIO $1.24
- 52 Week High
- ATNM $10.24
- FBIO $4.43
- Technical
- Relative Strength Index (RSI)
- ATNM 41.48
- FBIO 60.07
- Support Level
- ATNM $1.48
- FBIO $1.50
- Resistance Level
- ATNM $1.80
- FBIO $1.65
- Average True Range (ATR)
- ATNM 0.12
- FBIO 0.08
- MACD
- ATNM 0.04
- FBIO 0.04
- Stochastic Oscillator
- ATNM 54.44
- FBIO 91.11
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.